Zobrazeno 1 - 10
of 29
pro vyhledávání: '"S, Nimnual"'
Autor:
Edward L. Chan, Michael J. Hayman, Kristen A. VanHeyst, Mathew S. Varghese, Anjaruwee S. Nimnual, James Keller
EGFR is a popular therapeutic target for many cancers. EGFR inhibitors have been tested in children with refractory neuroblastoma. Interestingly, partial response or stable disease was observed in a few neuroblastoma patients. As EGFR mutations are b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f6fb17ff61c415d41524515808c4667
https://doi.org/10.1158/1541-7786.c.6539950.v1
https://doi.org/10.1158/1541-7786.c.6539950.v1
Autor:
Edward L. Chan, Michael J. Hayman, Kristen A. VanHeyst, Mathew S. Varghese, Anjaruwee S. Nimnual, James Keller
S6. These clones were used for the XTT assay.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fdd0adc9c8175cd9dee02e222de42aa
https://doi.org/10.1158/1541-7786.22511479
https://doi.org/10.1158/1541-7786.22511479
Autor:
Edward L. Chan, Michael J. Hayman, Kristen A. VanHeyst, Mathew S. Varghese, Anjaruwee S. Nimnual, James Keller
Supplemental Figure Legends 1-7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09425856a411976d6858abf390b84066
https://doi.org/10.1158/1541-7786.22511464
https://doi.org/10.1158/1541-7786.22511464
Autor:
Edward L. Chan, Michael J. Hayman, Kristen A. VanHeyst, Mathew S. Varghese, Anjaruwee S. Nimnual, James Keller
S5. Concentrations of erlotinib ranged from 0.025 - 2.5 uM. MW: molecular weight; Tx: treatment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9782f40d3b4efd19786ca5d6f400e7f6
https://doi.org/10.1158/1541-7786.22511485
https://doi.org/10.1158/1541-7786.22511485
Autor:
Edward L. Chan, Michael J. Hayman, Kristen A. VanHeyst, Mathew S. Varghese, Anjaruwee S. Nimnual, James Keller
S4. n = 6 for EGFRÎ"768 and n = 8 for GFP cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00f41e938de9b4061cb08b670ff3b1da
https://doi.org/10.1158/1541-7786.22511482.v1
https://doi.org/10.1158/1541-7786.22511482.v1
Autor:
Edward L. Chan, Michael J. Hayman, Kristen A. VanHeyst, Mathew S. Varghese, Anjaruwee S. Nimnual, James Keller
S7. EGFRvIII activation resulted in phosphorylation of EphA10, RYK and ALK in these cells. Noted the strong EGFRvIII phosphorylation signal detected by the array.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a356302cab362ccff7d412bc0fa21897
https://doi.org/10.1158/1541-7786.22511476
https://doi.org/10.1158/1541-7786.22511476
Autor:
Edward L. Chan, Michael J. Hayman, Kristen A. VanHeyst, Mathew S. Varghese, Anjaruwee S. Nimnual, James Keller
S1. All PCR products were confirmed to be either EGFRÎ"768 or EGFRvIII by bidirectional sequencing. Gel purified EGFRvIII and EGFRÎ"768 cDNA were positive controls. H2O was negative control.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50074366b33be235185a005111af1fbd
https://doi.org/10.1158/1541-7786.22511473.v1
https://doi.org/10.1158/1541-7786.22511473.v1
Autor:
Edward L. Chan, Michael J. Hayman, Kristen A. VanHeyst, Mathew S. Varghese, Anjaruwee S. Nimnual, James Keller
S3. STR profiles of BE(2)C, BE(2)-M17 and IMR32.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28ce4c0f735ae8b6d4d3998e26ee7e8f
https://doi.org/10.1158/1541-7786.22511467
https://doi.org/10.1158/1541-7786.22511467
Autor:
Edward L. Chan, Michael J. Hayman, Kristen A. VanHeyst, Mathew S. Varghese, Anjaruwee S. Nimnual, James Keller
S2. All PCR products were confirmed to be either EGFRÎ"768 or EGFRvIII by bidirectional sequencing. Black arrows indicated EGFRÎ"768 and white arrows pointed to EGFRvIII. H2O was negative control.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a67aaae5b3336e8f5938adae984e5a9
https://doi.org/10.1158/1541-7786.22511470
https://doi.org/10.1158/1541-7786.22511470
Autor:
Michael J. Hayman, Edward L. Chan, Mathew S. Varghese, Kristen A. VanHeyst, James Keller, Anjaruwee S. Nimnual
Publikováno v:
Molecular Cancer Research. 14:740-752
EGFR is a popular therapeutic target for many cancers. EGFR inhibitors have been tested in children with refractory neuroblastoma. Interestingly, partial response or stable disease was observed in a few neuroblastoma patients. As EGFR mutations are b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad15acbf558b43d119d4c1525900c54f
https://doi.org/10.1158/1541-7786.mcr-15-0477
https://doi.org/10.1158/1541-7786.mcr-15-0477
